No Coagulation Disorders under High-Dose Volume Therapy with Low-Molecular-Weight Hydroxyethyl Starch

Abstract

Hydroxyethyl starch (HES) is often used for volume therapy. Since bleeding complications have been reported repeatedly, a strict dose limitation of a maximum of 1,500 ml 6% solution per day is recommended. However, many indications require higher dosages. Bleeding complications are known to be caused by an acquired von Willebrand syndrome. It has been shown that the accumulation of large molecules and their impairment in the coagulation system can be avoided by using HES preparations with a low in vivo molecular weight. However, the effects of a high-dose therapy have not been studied yet. We have investigated, how a 4-day high-dose therapy, using 3,000 ml 6% HES 70/0.5 on the 1st day and 1,500 ml on days 2-4, affects the coagulation system and hemorheological parameters of acute stroke patients. Thromboplastin time, activated partial thromboplastin time and thrombin time showed no significant changes, except for a slight, clinically irrelevant change due to dilution. The subunits of von Willebrand factor VIII showed no significant change. Hematocrit decreased from 42.3 ± 4.6 to 37.4 ± 3.9% (p < 0.05) after day 1, reaching 35.3 ± 4.2% (p < 0.01) at the end of the therapy, demonstrating a substantial volume effect. Plasmaviscosity and erythrocyte aggregation decreased slightly, however not significantly. Our study shows that even a high-dose therapy with 6% HES 70/0.5 has no influence on the coagulation system.

Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery

“…Although HES may influence blood coagulation, its safe use during intracranial procedures has been demonstrated 21. Since 2003, a different formula of HES with less affect on coagulation was used 16.…”

Emergency Subtotal Colectomy in a Jehovah’s Witness With Massive Lower Gastrointestinal Bleeding: Challenges Encountered and Lessons Learned

“…Low-molecular-weight hydroxyethyl starch may be better than its high-molecular-weight counterpart, which has antiplatelet properties and adverse effects on coagulation. 5 Mackenzie et al 6 reported using a hemoglobin-based acellular oxygen-carrying solution (HBOC-201) in a Jehovah's Witness with traumatic hemorrhagic shock when the patient's hemoglobin level reached a low of 4.5 mg/dL;…”

A Systematic Review of the Comparative Safety of Colloids

“…Thus, in cardiac surgery studies with albumin as the control, HES has resulted in platelet depletion and dysfunction, prothrombin time and activated partial thromboplastin time prolongation, and increased postoperative bleeding. ‡ One NCT of 444 patients revealed significant increases in blood product use, as well as postoperative blood loss, in patients receiving HES †References 27,29,34,40,61,62,69,78,80,82,94,103,104. ‡References 3,11,13,15,17,46,48,50,65,92.…”